Objective: In the absence of specific metabolic disorders, accurate predictors of response to ketogenic dietary therapies (KDTs) for treating epilepsy are largely unknown. We hypothesized that specific biochemical parameters would be associated with the effectiveness of KDT in humans with epilepsy. The parameters tested were b-hydroxybutyrate, acetoacetate, nonesterified fatty acids, free and acylcarnitine profile, glucose, and glucose-ketone index (GKI). Methods: Biochemical results from routine blood tests conducted at baseline prior to initiation of KDT and at 3-month follow-up were obtained from 13 adults and 215 children with KDT response data from participating centers. One hundred thirty-two (57%) of 228 participants had some data at both baseline and 3 months; 52 (23%) of 228 had data only at baseline; 22 (10%) of 228 had data only at 3 months; and 22 (10%) of 228 had no data. KDT response was defined as ≥50% seizure reduction at 3-month follow-up. Results: Acetyl carnitine at baseline was significantly higher in responders (p < 0.007). It was not associated with response at 3-month follow-up. There was a trend for higher levels of free carnitine and other acylcarnitine esters at baseline and at 3-month follow-up in KDT responders. There was also a trend for greater differences in levels of propionyl carnitine and in b-hydroxybutyrate measured at baseline and 3-month follow-up in KDT responders. No other biochemical parameters were associated with response at any time point. Significance: Our finding that certain carnitine fractions, in particular baseline acetyl carnitine, are positively associated with greater efficacy of KDT is consistent with the theory that alterations in energy metabolism may play a role in the mechanisms of action of KDT.
patients, those with higher prediet seizure frequency or specific electroencephalography (EEG) parameters, is inconsistent. 6 High response rates have been observed in certain epilepsy syndromes 7 and individuals with focal malformations, 8, 9 but these are merely indications; there are still nonresponders within these groups, and the question remains whether other patient demographics or clinical parameters allow response to KDTs to be predicted. Prior to commencing a KDT, individuals are screened with biochemical testing of blood and urine for disorders of fatty acid metabolism and organic acidurias. Blood levels of various vitamins, minerals, and electrolytes (depending on local practice) are also measured and monitored throughout treatment.
Previous studies have examined potential associations between KDT response and b-hydroxybutyrate (BHB), the primary circulating ketone body in response to starvation and/or KDT, 10 but results have been inconsistent. [11] [12] [13] Other biochemical parameters that are already measured as part of routine clinical practice could theoretically be associated with KDT response based on their role in fat and carbohydrate metabolism. For example, acetoacetate, akin to BHB, can be converted back to acetyl-CoA for entry into the citric acid cycle and thus used as an energy source; nonesterified fatty acids (NEFAs) are precursors of ketone bodies and flux to the liver is increased in individuals following KDT 14 ; carnitine and acylcarnitine esters (measured by the acylcarnitine profile) are essential for mitochondrial uptake of long-chain fatty acids; and reduced glucose levels (but stable and within physiologic range) are a natural consequence of consuming a low-carbohydrate diet and are necessary for ketone production, which occurs in response to reduced hepatic glycogen stores. The relationship between glucose and BHB levels may also be important for KDT response: a lower glucose-ketone index (GKI), the ratio of blood glucose to ketones, has been found to be associated with greater efficacy of ketogenic diets (or calorie restriction) for brain tumor management in mice and humans. 15 There is very limited evidence suggesting lack of association between carnitine (unclear whether measured at baseline or follow-up) 13 and KDT response; evidence regarding KDT response and glucose, including measures at baseline, follow-up, and differences between the two time-points, is conflicting. [16] [17] [18] [19] No studies have examined the possible association between acylcarnitine esters, acetoacetate, NEFAs, or calculated GKI and the effectiveness of KDT in humans with epilepsy. We hypothesized that these parameters are associated with response to KDT.
Methods

Ethics and recruitment
Biochemical data were obtained from participants of a study investigating the genetic basis behind response to KDT. 20, 21 The project gained ethical approval through relevant ethics committees or institutional review boards. Written informed consent was obtained from all study participants or from their parents/carers in the case of minors or adults with intellectual disability.
Participants were recruited for the study from Criteria for study inclusion were the following: individuals aged ≥3 months who were either following KDT or who had followed KDT in the past for epilepsy. Exclusion criteria were individuals who discontinued KDT before the 3-month point due to lack of tolerability (those who discontinued KDT before the 3-month point due to lack of response or seizure increase were included), and individuals with progressive myoclonic epilepsies or other progressive neurologic diseases.
Data collection
All participants underwent electroclinical phenotyping to establish seizure type and epilepsy syndrome. This involved evaluation of medical history, seizure semiology, examination, and review of EEG and imaging studies. Demographic data were obtained from medical records. Biochemical results for BHB, acetoacetate, NEFA, free carnitine and acylcarnitine profile, and glucose conducted at baseline (prior to initiation of KDT) and at 3-month follow-up (3 months after KDT was started) as part of routine clinical care were obtained from medical records and National Health Service (NHS) Trust databases. The GKI was calculated using the GKI calculator using glucose and BHB levels measured at baseline and at 3-month follow-up. 15 KDT response was defined as a function of seizure frequency, as published previously. 20, 21 Response was Key Points • Pre-diet acetyl carnitine is associated with ketogenic diet response
• There is a trend for higher levels of free carnitine and other acylcarnitine esters in responders
• Acetyl carnitine is reversibly converted to acetylCoA, which may enter the citric acid cycle or be used to produce ketones estimated in 28-day epochs prior to starting the diet (baseline) and prior to 3-month follow-up after the start of KDT. Clinic letters and seizure diaries, where already used as part of clinical monitoring, were used to estimate seizure frequency at each time point. The calculation used to determine percentage reduction in seizure frequency was [(a-b)/ a] 9 100, where a = number of seizures in the 28 days prior to KDT initiation; and b = number of seizures in the 28 days preceding the 3-month point. A case/control observational study design was adopted. Those with ≥50% seizure reduction were classified as "responders"; those with <50% seizure reduction were "nonresponders." Seizure freedom achieved at 3-month follow-up was also documented.
Statistical analyses
The effect of demographic parameters between groups with biochemical data at various time points (either with no biochemical data, some data at baseline and 3-month follow-up, data only at baseline, or data only at 3-month follow-up) was assessed using Fisher's exact or KruskalWallis tests. The effect of demographic parameters on KDT response was assessed using Fisher's exact or KruskalWallis tests.
Parametric tests were conducted to assess the relationship between KDT response at 3-month follow-up and blood test results that had ≥50 data points in each response group. Nonparametric analyses were used for blood test results with <50 data points in each response group. Analyses were conducted with biochemical results from baseline, at 3-month follow-up, and using the difference between the biochemical results taken at these two time points.
A significance threshold of 0.05 was applied, as this was an exploratory analysis. The Bonferroni-corrected significance threshold to account for the multiple testing of 14 tests was a = 0.004. Note that this correction is too conservative, as our tests are not independent of each other.
All statistics were performed in Stata v13.1 (Stata Statistical Software: Release 13; StataCorp LP, College Station, TX, U.S.A.).
Results
Response data could not be collected for 4 (2%) of 232 participants, which is a small enough proportion to safely ignore dropout without fear of biasing our results. One hundred seventeen (51%) of 228 participants (113 children and 4 adults [aged ≥18 years at start of diet]) had ≥50% seizure reduction after 3 months of following KDT, of whom 10 were seizure-free (all aged <18 years); and 111(49%) of 228 (102 children and 9adults) had <50% seizure reduction. There was no statistically significant difference in response between children and adults (Fisher's exact test, p = 0.16).
One hundred thirty-two (58%) of 228 participants with KDT response data had some data at both baseline and 3-months; 52 (23%) of 228 had data only at baseline; 22 (10%) of 228 had data only at 3-months; 22 (10%) of 228 had no data available.
A summary of the clinical and demographic parameters of the cohort are given in Table S1 . No participants received carnitine supplementation either at baseline or during KDT.
There was no difference in demographic parameters between groups with biochemical data at various time points, as shown in Tables S2-S9 . No analyses were conducted for cause of epilepsy or for epilepsy syndrome, as, for most participants, the cause was "unknown" and they had no syndromic diagnosis.
There was no difference in any demographic parameter between responders and nonresponders to KDT when response was defined as 50% seizure reduction, as shown in Table S10 .
There was a trend for lower age at diet start in those who achieved seizure freedom compared to those who did not become seizure-free (median age was 3.4 years in those who became seizure-free, and median age was 5.7 years in those who did not achieve seizure freedom; p = 0.02). There was no difference in any other demographic parameters when response was defined as seizure freedom, as shown in Table S10 .
Acetyl carnitine at baseline was higher in KDT responders (uncorrected p < 0.003; Table 1 ). This is significant, even when applying a Bonferroni-corrected significance threshold (p < 0.004).
Acetyl carnitine data at baseline ranged from 2.74 to 40.7 lmol/L for responders and 3.59-32.5 lmol/L for nonresponders. Figure 1 shows a trend for higher acetyl carnitine levels at baseline in responders, although at the lower end of the scale (acetyl carnitine levels approximately <7 lmol/L), there is some overlap between responders and nonresponders.
There were trends for higher free, propionyl, octanoyl, and palmitoyl carnitine and b-hydroxybutyrate at baseline in KDT responders (p < 0.05 but > 0.004; Table 1 ), higher palmitoyl carnitine at 3-month follow-up in KDT responders (p < 0.05 but > 0.004; Table 2 ), and greater differences in levels of propionyl carnitine and in BHB measured at baseline and 3-month follow-up in KDT responders (p < 0.05 but > 0.004; Table 3 ).
There was a trend for higher NEFA levels at 3-month follow-up and a greater difference in BHB levels at baseline and at 3-month follow-up in participants who achieved seizure freedom at 3-month follow-up compared to those who were not seizure-free (p < 0.05 but > 0.004). These data are presented in Tables S11-S13.
Discussion
We have found that acetyl carnitine at baseline was significantly higher in KDT responders compared to responders, although the effect size is small and potential clinical significance unknown. This result is supported by a trend for higher levels of free carnitine and other acylcarnitine esters in KDT responders at baseline, 3-month follow-up, or the difference in levels measured at these two time points. We are not aware of previously published reports of a relationship between acetyl carnitine, or any other acylcarnitine esters, and KDT response.
Our finding that higher blood acetyl carnitine levels are associated with greater effectiveness of KDT is consistent with our knowledge of biochemistry: carnitine is needed to transport long-chain fatty acids into hepatic mitochondria to produce ketones and acetyl carnitine, and acetyl coenzyme A (acetyl-CoA) plays a critical role in mitochondrial energy metabolism. There is an equilibrium between acetyl carnitine (acetyl-CoA + carnitine) and acetyl-CoA. Acetyl carnitine is reversibly converted to acetyl-CoA by carnitine acetyltransferase (CAT) enzymes 22 (see Fig. 2 ). This maintains acetyl-CoA levels for production of ketone bodies (acetyl carnitine then leaves the mitochondria with the ketones) and for entry of acetyl-CoA into the citric acid cycle. Levels of acylcarnitines, including acetyl carnitine, are increased in patients following KDT. 23 These metabolic adaptations, triggered by peroxisome proliferator-activated receptor alpha (PPARa), serve to favor the use of ketones as fuel. 24 Our findings may point to a targetable alteration in energy metabolism and acetyl CoA buffering/availability. Although the mechanisms responsible for this observation are unknown, this result may relate to our recent reports that decanoic acid, a component of the medium chain triglyceride (MCT) KD, can increase citrate synthase activity in both cultured neurons and fibroblasts. 25, 26 This enzyme utilizes acetyl CoA and catalyzes the first reaction of the citric acid cycle (the condensation of acetyl-CoA and oxaloacetate to form citrate). We may have identified a subset of patients that responded to KDT due to improvement in mitochondrial energy metabolism. The fact that acetyl carnitine at 3-month follow-up was not associated with response to KDT in our study may reflect the fact that these patients' "deficiencies" in mitochondrial bioenergetics have been "corrected" through use of KDT. One could infer that acetyl carnitine is important for successfully starting KDT, but once ketosis has been achieved and/or mitochondrial energy metabolism is altered, carnitine levels are no longer associated with seizure control. However, it is unknown whether the serum biochemical parameters looked at in our study reflect cerebral energy metabolism.
One study previously investigated the relationship between carnitine (it is unclear whether this was free or total carnitine) and KDT response 13 ; no statistically significant Box and whisker plot of acetyl carnitine (lmol/L) at baseline for ketogenic diet responders and nonresponders. The box and whisker plot shows the distribution of data for responders and nonresponders divided into quartiles, highlighting the mean (9), median (À), and outliers. Epilepsia ILAE Table 1 . Relationship between KDT response at 3-month follow-up with biochemical parameters at baseline 27 than nonresponders; there are also reports of a positive correlation between reduction in seizure frequency and elevation in serum total arachidonic acid compared to pre-diet levels, 28 higher serum palmitoleic acid in responders after 1 month, lower serum arachidonic acid in responders after 1 month, and lower serum arachidonic and docosahexaenoic in responders at 3-month follow-up. 29 However, no difference has been found in levels of other plasma fatty acids, 27 monoamine or homovanillic acid (HVA)/5-hydroxyindoleacetic acid (5H1AA), 30 linoleic acid or alpha-linolenic acid, 29 or octanoic or decanoic acid 31 between responders and nonresponders. We found a trend for association between KDT response-both defined as ≥50% seizure reduction and seizure freedom-and the difference in blood BHB levels at baseline and 3-month follow-up. This is a novel approach to analyzing the relationship between BHB and KDT effectiveness. Some studies have previously reported a correlation between improved seizure control at various follow-up points and higher blood BHB levels in children, 11, 12, 32, 33 adolescents, 11, 12 and adults 12 following KDT. Others have found no correlation, either with blood BHB or urinary ketosis in all KD variants, with use of the classical diet, MCT diet, Modified Atkins diet/Modified Ketogenic Therapy, and the Low Glycemic Index Treatment (see Ref. 6 for a comprehensive list of references). BHB has been shown to have direct 34 and indirect 35 neuroprotective and/or anticonvulsant effects, and ketone esters have displayed anticonvulsant properties in animal seizure models, [36] [37] [38] which supports the premise that the production of ketones is necessary for effectiveness of KDT. On the other hand, recent studies found that medium chain fatty acids, specifically decanoic acid, displayed antiseizure activity (although this has not yet been tested in humans), whereas BHB did not, 25, 26, 39 pointing toward alternative therapeutic mechanisms of KDT. We also found a trend for higher NEFA levels at 3-month follow-up in participants who achieved seizure freedom at 3 months; no other studies were found assessing the relationship between total NEFA and KDT response.
We did not find that GKI, either at baseline or at 3 months, was associated with KDT effectiveness. We hoped to investigate the difference in the GKI values taken at the two time points, but the baseline results were much higher; thus it would have mainly reflected the effect of the baseline values. Furthermore, no relationship was seen with glucose alone, showing that the GKI trends are driven by BHB levels. A more accurate and consistent measurement of GKI could be obtained by measuring blood glucose and BHB twice a day, 2-3 h postprandially, at approximately the same time of day for each patient, as suggested in the manuscript that originally discussed the concept of GKI. 15 Our findings are not affected by differences in demographic parameters between KDT responders and nonresponders, or between groups with biochemical data at various time points. Age at diet start was lower in those who achieved seizure freedom, but there were only 10 participants in this group, compared with 218 who did not achieve seizure freedom. This correlation may have been related to epilepsy syndrome; many participants did not have a syndromic diagnosis and, for those who did, the numbers within each syndrome group were too small for statistical analysis. Although some studies have reported a more favorable response in younger children or infants, the majority have found that age makes no difference (see Schoeler et al. 6 for a detailed list of references).
We may have been underpowered to detect the small effect sizes of certain biochemical parameters (in particular, other acylcarnitine esters, BHB and NEFA), leading to nonsignificant results when accounting for multiple testing. Although large effect sizes would be more beneficial when considering translation into clinical practice, factors with small effect sizes may provide insight into the mechanisms of action of KDT. There were missing data in our cohort and very few participants achieved seizure freedom. Missing data may have occurred because some blood tests were performed at local hospitals and were not recorded in the databases of participating centers. Despite missing data, with 56 responders and 56 nonresponders with baseline acetyl carnitine data, any concentration error estimates in the laboratory values should be spread evenly within the two groups. Our results are worth following up in a larger cohort, particularly with a larger number of seizure-free patients.
Another limitation of the study is that KDT response data were collected retrospectively, predominantly from clinic letters. Ideally, seizure diaries would be used throughout the 3-month period to allow for the natural variability of seizures over time, rather than relying on 28-day epochs. Seizure recording throughout the entire follow-up period may be crucial for individuals whose seizures occur in weekly/ monthly clusters; seizure reduction on the diet may not be accurately reflected by using 28-day epochs, as the cluster may occur just before the 28 days prior to baseline and so, according to the seizure diary, the patient would be seizurefree before starting the diet. This was not an issue for any of our participants, as they all had seizures in the 28 days prior to baseline. Completion of a seizure diary for any prolonged length of time, however, can be burdensome for patients and/or carers. A 3-month baseline period before starting KDT may also be prohibitively long for some patients. Prospective data collection may have resulted in fewer missing data points and have allowed the possibility of ensuring a more consistent procedure for timing of blood collection-this would be particularly important for glucose and BHB levels. However, this would be difficult to achieve in an outpatient setting.
There are possible analyses that could be performed in a follow-up study. If seizure diaries were used for all participants, we could use percentage seizure frequency change directly as a response variable; much information is lost when using binary outcomes. We could also perform a multivariable regression of our biochemical markers, as many of our measurements were correlated.
Conclusion
We have found a previously unreported relationship between acetyl carnitine at baseline and KDT response. This provides supporting evidence for the role of altered mitochondrial energy metabolism in the mechanisms of action of KDT. We also report a trend for association with free and other acylcarnitine esters, either at baseline, at 3-month follow-up, or the difference between results at these two time points. Our findings also add to the conflicting evidence that blood BHB levels are associated with a KDT response. These results are worth following up in a larger cohort; although the relationship between baseline acetyl carnitine and KDT response is significant, the effect size is small and thus the finding has limited clinical meaning until followed up with a more controlled prospective study. Confirming the association would aid our understanding of the mechanisms of action of KDT and could potentially be used to target resources toward patients who are more likely to response favorably to KDT.
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